Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 529 clinical trials
Decitabine Venetoclax and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

This phase II trial studies how well the combination of decitabine, venetoclax, and ponatinib work for the treatment of Philadelphia chromosome-positive acute myeloid leukemia or myeloid blast phase or accelerated phase chronic myelogenous leukemia. Drugs used in chemotherapy such as decitabine, work in different ways to stop the growth of …

ponatinib
serum lipase
myeloid leukemia
decitabine
chronic myeloid leukemia
  • 0 views
  • 06 Nov, 2021
  • 1 location
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for …

lung cancer
neutrophil count
measurable disease
EGFR
ct scan
  • 0 views
  • 31 May, 2021
  • 1 location
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Pfizer's innovative drug palbociclib (trade name: Ibrance) got China National Drug Administration (CNDA) approval on July 31, 2018. Palbociclib combined with an aromatase inhibitor can be used to treat hormone receptor-positive/human epidermal growth factor receptor 2-negative locally advanced breast cancer or metastatic breast cancer. This brings more treatment options for …

aromatase inhibitor
mammogram
erbb2
growth factor
epidermal growth factor
  • 0 views
  • 31 Jul, 2021
  • 3 locations
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

bone marrow procedure
measurable disease
progressive disease
refractory multiple myeloma
cancer
  • 0 views
  • 17 Oct, 2021
  • 9 locations
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (GMMG-DADA)

Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)

dexamethasone
lenalidomide
bortezomib
  • 0 views
  • 23 Apr, 2022
  • 1 location
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

The purpose of the CaboAveNEC trial is to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3).

platelet count
neutrophil count
  • 0 views
  • 19 Apr, 2022
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Stereotactic body radiation therapy uses special equipment to …

  • 0 views
  • 14 Oct, 2021
  • 1 location
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

Zanubrutinib is a highly specific, potent new Bruton's tyrosine kinase (BTK) inhibitor, with minimal off-target inhibition of other kinases. This is a single-arm, open-label Phase II study to evaluate the efficacy and safety of zanubrutinib in combination with Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in newly diagnosed non-GCB Diffuse …

Accepts healthy volunteers
  • 0 views
  • 14 Mar, 2022
  • 1 location
Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment (CSA)

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions …

apnea-hypopnea index
heart failure
opioid
central sleep apnea
Accepts healthy volunteers
  • 0 views
  • 23 Mar, 2022
  • 1 location
CIML NK Cell in Head & Neck Cancer

This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: CIML NK donor cells IL-15 superagonist Ipilimumab

oropharyngeal
neutrophil count
head and neck cancer
prednisone
cancer
  • 0 views
  • 05 May, 2022